0001567619-22-013869.txt : 20220711
0001567619-22-013869.hdr.sgml : 20220711
20220711161513
ACCESSION NUMBER: 0001567619-22-013869
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220707
FILED AS OF DATE: 20220711
DATE AS OF CHANGE: 20220711
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Quan Lucinda Y.
CENTRAL INDEX KEY: 0001824711
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39617
FILM NUMBER: 221077096
MAIL ADDRESS:
STREET 1: C/O ALIGOS THERAPEUTICS, INC.
STREET 2: ONE CORPORATE DRIVE, 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aligos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001799448
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (800) 466-6059
MAIL ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2022-07-07
0
0001799448
Aligos Therapeutics, Inc.
ALGS
0001824711
Quan Lucinda Y.
C/O ALIGOS THERAPEUTICS, INC.
1 CORPORATE DR
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
See Remarks
Stock Option (Right to Buy)
1.41
2022-07-07
4
A
0
52500
0.00
A
2032-07-07
Common Stock
52500
52500
D
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Executive Vice President, Chief Business Officer and General Counsel
/s/ Lucinda Y. Quan
2022-07-11